Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer

Stock Information for Celsion Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Celsion Corporation

Celsion Corporation Announces Company Name Change to Imunon, Inc.
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.